The primary objective is to estimate overall survival after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer
Patients must have histologically or cytologically confirmed recurrent primary mucinous ovarian cancer
Age ≥18 years
ECOG performance status ≤ 2
absolute neutrophil count >1,500/mcL
Patients who are receiving concurrent investigational therapy or who have received investigational therapy within 30 days of HIPEC (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)
Patients with mucinous tumors with pathologic confirmation of a non-gynecologic site of origin
Patients with known active CNS metastases
Patients with known hypersensitivity to any of the components of cisplatin
Single group
Cytoreductive surgery
Other intervention(an operation to remove as much tumor tissue as possible) with hyperthermic intraperitoneal chemotherapy
To estimate progression-free survival (PFS) after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer
Click on the lead sponsor to view all of their trials.
